Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Arrowhead Pharmaceuticals Inc (ARWR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Arrowhead Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
88.23 -0.60    -0.68%
14:56:56 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US04280A1007 
CUSIP:  04280A100
  • Volume: 672,148
  • Bid/Ask: 88.14 / 88.23
  • Day's Range: 87.42 - 93.55
Arrowhead Pharma 88.23 -0.60 -0.68%
IndustryBiotechnology
SectorHealthcare
Employees

232

Equity Type

ORD

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Contact Information

Top Executives

Name Age Since Title
Christopher Richard Anzalone 51 2007 President, Chief Executive Officer, Director
Kenneth Allen Myszkowski 54 2010 Chief Financial Officer
Mauro Ferrari 61 2010 Independent Director
Douglass Bruce Given 68 2013 Chairman of the Board
Michael S. Perry 61 2015 Lead Independent Director
Patrick C. O'Brien 57 2020 Chief Compliance Officer, General Counsel, Company Secretary
William D. Waddill 64 2018 Independent Director
Javier San Martin 51 2019 Chief Medical Officer
Curt W. Bradshaw 55 2019 Chief Scientific Officer
Marianne De Backer 53 2019 Independent Director
James Hassard 54 2020 Chief Commercial Officer
Oye Olukotun 76 2020 Independent Director
James Hamilton 43 - Senior Vice President, Discovery & Translational Medicine
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ARWR Comments

Write your thoughts about Arrowhead Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Duane Goodson
Duane Goodson Jan 04, 2021 11:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
Jiamin Xu
Jiamin Xu Oct 20, 2020 3:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dilution soon?
ari kelin
ari kelin Oct 20, 2020 3:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i think they just got a ton of $ from their new deal...doesn't mean won't dilute
Imtanis Farah
Imtanis Farah Sep 23, 2020 4:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Going to 69
Imtanis Farah
Imtanis Farah Sep 17, 2020 2:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Target price 76$
Tommy Nguyen
Tommy Nguyen Sep 17, 2020 2:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Upgrade?
Mr MARKET
Mr MARKET Sep 16, 2020 12:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pandemic covid19 Coronavirus has created massive never ever earning opportunities for biotechs pharmaceutical companies products investments...as its 7bn human beings effected need to be protected cured...supposing usd 100 each one spends on vaccines gloves sanitizers masks its huge mount Everest of earnings for biotechs pharma vaccines companies
Mr MARKET
Mr MARKET Sep 16, 2020 12:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
All pharma biotechs to shoot upwards rocket drive like Arrowhead today.....Trump clearly pushing forward indicating Coronavirus stimulus update: Trump suggests he could back bigger relief billhttps://www.cnbc.com/id/106704892?view=story?__source=androidappshare
Imtanis Farah
Imtanis Farah Sep 02, 2020 2:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Go for 57$
Joey Bigreturn
Joey Bigreturn Jun 12, 2020 3:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Go for 20$
Ivan Dimitrov
Ivan Dimitrov Mar 17, 2020 1:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it is a buy now
Michelle Saint
Michelle Saint Dec 03, 2019 2:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It's a buy
Yousef Abu Shaikh
Yousef Abu Shaikh Nov 27, 2019 10:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
to hit
Yousef Abu Shaikh
Yousef Abu Shaikh Nov 27, 2019 10:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it looks that it is going to hot mid 70's
Gozali Rahman
Gozali Rahman Nov 27, 2019 12:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
anyone thinking shorting this stock soon? seems overbought?
Yousef Abu Shaikh
Yousef Abu Shaikh Oct 23, 2019 8:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The increase is upnormal . Gambling
catalonia knows
catalonia knows Jun 05, 2019 1:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
back to 2014 highs?
catalonia knows
catalonia knows May 30, 2019 2:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hi!
Ling Pang
Ling Pang Oct 04, 2018 10:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Like a bargain at $16.34
Rens Oldebroek
Rens Oldebroek Sep 06, 2018 10:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It did!
SaYeD SaYeD
SaYeD SaYeD Jan 05, 2017 5:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ready to explode
SaYeD SaYeD
SaYeD SaYeD Jan 05, 2017 5:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
posted at 1.20 it will go to 4.0 guaranteed
jay am
jay am Jan 05, 2017 5:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Stock twit
Ric Ric
Ric Ric Jan 05, 2017 5:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It did...boom!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email